{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:33:37Z","timestamp":1791851617131,"version":"4.3.4"},"reference-count":119,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2005,8]]},"DOI":"10.4065\/80.8.1050","type":"journal-article","created":{"date-parts":[[2009,1,23]],"date-time":"2009-01-23T20:26:10Z","timestamp":1232742370000},"page":"1050-1057","source":"Crossref","is-referenced-by-count":198,"title":["Medication-Induced Hyperprolactinemia"],"prefix":"10.4065","volume":"80","author":[{"given":"Mark E.","family":"Molitch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4065\/80.8.1050_bib1","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0889-8529(05)70203-6","article-title":"Disorders of prolactin secretion","volume":"30","author":"Molitch","year":"2001","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.4065\/80.8.1050_bib2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0889-8529(18)30442-0","article-title":"Prolactin and neuroleptic drugs","volume":"17","author":"Green","year":"1988","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.4065\/80.8.1050_bib3","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1136\/bmj.324.7332.250","article-title":"Hyperprolactinaemia caused by antipsychotic drugs [editorial]","volume":"324","author":"Wieck","year":"2002","journal-title":"BMJ"},{"key":"10.4065\/80.8.1050_bib4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0306-4530(80)90015-3","article-title":"The prolactin secretory response to neuroleptic drugs: mechanisms, applications and limitations","volume":"5","author":"Rubin","year":"1980","journal-title":"Psychoneuroendocrinology"},{"key":"10.4065\/80.8.1050_bib5","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1172\/JCI106643","article-title":"Human prolactin: measurement in plasma by in vitro bioassay","volume":"50","author":"Kleinberg","year":"1971","journal-title":"J Clin Invest"},{"key":"10.4065\/80.8.1050_bib6","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0306-4530(77)90007-5","article-title":"Dopaminergic factors in human prolactin regulation: effects of neuroleptics and dopamine","volume":"2","author":"Langer","year":"1977","journal-title":"Psychoneuroendocrinology"},{"key":"10.4065\/80.8.1050_bib7","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1210\/jcem-45-5-996","article-title":"The prolactin response to neuroleptic drugs: a test of dopaminergic blockade: neuroendocrine studies in normal men","volume":"45","author":"Langer","year":"1977","journal-title":"J Clin Endocrinol Metab"},{"issue":"5, pt 1","key":"10.4065\/80.8.1050_bib8","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0029-7844(98)00066-0","article-title":"Pattern of development of hyperprolactinemia after initiation of haloperidol therapy","volume":"91","author":"Spitzer","year":"1998","journal-title":"Obstet Gynecol"},{"key":"10.4065\/80.8.1050_bib9","series-title":"Hormones, Behavior, and Psychopathology","first-page":"177","article-title":"Serum prolactin levels in schizophrenia\u2014effect of antipsychotic drugs: a preliminary report","author":"Meltzer","year":"1976"},{"key":"10.4065\/80.8.1050_bib10","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1365-2265.1976.tb01953.x","article-title":"Effect of acute and chronic neuroleptic therapy on serum prolactin levels in men and women of different age groups","volume":"5","author":"Rivera","year":"1976","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.4065\/80.8.1050_bib11","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1046\/j.1365-2265.1998.00569.x","article-title":"Serum prolactin concentration in patients taking neuroleptic drugs","volume":"49","author":"Pollock","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.4065\/80.8.1050_bib12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/00004714-200204000-00002","article-title":"The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis","volume":"22","author":"Smith","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"10.4065\/80.8.1050_bib13","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/0006-3223(95)00589-7","article-title":"High plasma prolactin levels after long-term neuroleptic treatment","volume":"39","author":"Zelaschi","year":"1996","journal-title":"Biol Psychiatry"},{"key":"10.4065\/80.8.1050_bib14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/00004714-199902000-00011","article-title":"Prolactin levels and adverse events in patients treated with risperidone","volume":"19","author":"Kleinberg","year":"1999","journal-title":"J Clin Psychopharmacol"},{"issue":"suppl 2","key":"10.4065\/80.8.1050_bib15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0306-4530(02)00127-0","article-title":"Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone","volume":"28","author":"Kinon","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"10.4065\/80.8.1050_bib16","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3109\/10401230209147453","article-title":"The effects of atypical antipsychotics on serum prolactin levels","volume":"14","author":"Hamner","year":"2002","journal-title":"Ann Clin Psychiatry"},{"issue":"suppl 2","key":"10.4065\/80.8.1050_bib17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0306-4530(02)00128-2","article-title":"Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials","volume":"28","author":"Kinon","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"10.4065\/80.8.1050_bib18","doi-asserted-by":"crossref","first-page":"425","DOI":"10.4158\/EP.6.6.425","article-title":"Risperidone-associated hyperprolactinemia","volume":"6","author":"Kearns","year":"2000","journal-title":"Endocr Pract"},{"key":"10.4065\/80.8.1050_bib19","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0149-2918(00)80086-7","article-title":"The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia","volume":"22","author":"David","year":"2000","journal-title":"Clin Ther"},{"key":"10.4065\/80.8.1050_bib20","doi-asserted-by":"crossref","first-page":"761","DOI":"10.4088\/JCP.v64n0704","article-title":"Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients","volume":"64","author":"Becker","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.4065\/80.8.1050_bib21","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.4088\/JCP.v64n1113","article-title":"Prolactin levels during long-term risperidone treatment in children and adolescents","volume":"64","author":"Findling","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.4065\/80.8.1050_bib22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4088\/JCP.v65n0109","article-title":"Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol","volume":"65","author":"Volavka","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.4065\/80.8.1050_bib23","first-page":"379","article-title":"Relation of serum molindone levels to serum prolactin levels and antipsychotic response","volume":"50","author":"Pandurangi","year":"1989","journal-title":"J Clin Psychiatry"},{"key":"10.4065\/80.8.1050_bib24","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1176\/ajp.156.2.294","article-title":"Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response","volume":"156","author":"Breier","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.4065\/80.8.1050_bib25","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1176\/appi.ajp.159.1.133","article-title":"Elevation of prolactin levels by atypical antipsychotics","volume":"159","author":"Turrone","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.4065\/80.8.1050_bib26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0920-9964(97)00036-4","article-title":"The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations","volume":"26","author":"Crawford","year":"1997","journal-title":"Schizophr Res"},{"key":"10.4065\/80.8.1050_bib27","doi-asserted-by":"crossref","first-page":"408","DOI":"10.4088\/JCP.v63n0506","article-title":"Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone","volume":"63","author":"Kim","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.4065\/80.8.1050_bib28","first-page":"107","article-title":"Plasma prolactin in schizophrenia subjects treated with SeroquelT (ICI 204,636)","volume":"32","author":"Hamner","year":"1996","journal-title":"Psychopharmacol Bull"},{"key":"10.4065\/80.8.1050_bib29","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/00004714-199808000-00009","article-title":"An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder","volume":"18","author":"Goff","year":"1998","journal-title":"J Clin Psychopharmacol"},{"key":"10.4065\/80.8.1050_bib30","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00213-002-1344-3","article-title":"Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study","volume":"166","author":"Casey","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"10.4065\/80.8.1050_bib31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/070674370204700106","article-title":"Atypical antipsychotics: mechanism of action","volume":"47","author":"Seeman","year":"2002","journal-title":"Can J Psychiatry"},{"key":"10.4065\/80.8.1050_bib32","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/archpsyc.60.10.974","article-title":"Mechanism of new antipsychotic medications: occupancy is not just antagonism","volume":"60","author":"Gr\u00fcnder","year":"2003","journal-title":"Arch Gen Psychiatry"},{"issue":"suppl 1","key":"10.4065\/80.8.1050_bib33","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0306-4530(02)00113-0","article-title":"Sexual dysfunction and antipsychotic treatment","volume":"28","author":"Cutler","year":"2003","journal-title":"Psychoneuroendocrinology"},{"issue":"suppl 2","key":"10.4065\/80.8.1050_bib34","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0306-4530(02)00130-0","article-title":"What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning?","volume":"28","author":"Knegtering","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"10.4065\/80.8.1050_bib35","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1043-6618(03)00174-9","article-title":"Risperidone-associated hyperprolactinemia: evaluation in twenty psychiatric outpatients","volume":"48","author":"Brunelleschi","year":"2003","journal-title":"Pharmacol Res"},{"key":"10.4065\/80.8.1050_bib36","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/01.jcp.0000106220.36344.04","article-title":"A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning","volume":"24","author":"Knegtering","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"10.4065\/80.8.1050_bib37","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S0015-0282(16)60365-5","article-title":"Bone density and reproductive hormones in patients with neuroleptic-induced hyperprolactinemia","volume":"50","author":"Ataya","year":"1988","journal-title":"Fertil Steril"},{"key":"10.4065\/80.8.1050_bib38","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1176\/appi.ajp.161.5.918","article-title":"Growth and sexual maturation during long-term treatment with risperidone","volume":"161","author":"Dunbar","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.4065\/80.8.1050_bib39","series-title":"Typical and Atypical Antidepressants: Clinical Practice","first-page":"303","article-title":"Effect of antidepressants on neuroendocrine axis in humans","author":"Meltzer","year":"1982"},{"key":"10.4065\/80.8.1050_bib40","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/archpsyc.1989.01810070051009","article-title":"Effects of desipramine and fluvoxamine treatment on the prolactin response to tryptophan: serotonergic function and the mechanism of antidepressant action","volume":"46","author":"Price","year":"1989","journal-title":"Arch Gen Psychiatry"},{"issue":"suppl 4","key":"10.4065\/80.8.1050_bib41","first-page":"166","article-title":"Plasma prolactin concentrations in normal subjects and depressive patients following oral clomipramine","volume":"53","author":"Jones","year":"1977","journal-title":"Postgrad Med J"},{"key":"10.4065\/80.8.1050_bib42","first-page":"851","article-title":"Management of psychotropic-induced hyperprolactinemia","volume":"11","author":"Marken","year":"1992","journal-title":"Clin Pharm"},{"key":"10.4065\/80.8.1050_bib43","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0140-6736(77)90956-4","article-title":"Elevation of plasmaprolactin by monoamine-oxidase inhibitors","volume":"2","author":"Slater","year":"1977","journal-title":"Lancet"},{"key":"10.4065\/80.8.1050_bib44","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/0024-3205(85)90515-6","article-title":"Effects of tranylcypromine treatment on neuroendocrine, behavioral, and autonomic responses to tryptophan in depressed patients","volume":"37","author":"Price","year":"1985","journal-title":"Life Sci"},{"key":"10.4065\/80.8.1050_bib45","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/00012995-199806000-00001","article-title":"Drug therapy and hyperprolactinaemia","volume":"190","author":"Cohen","year":"1998","journal-title":"Adv Drug Reaction Bull"},{"issue":"1, pt 1","key":"10.4065\/80.8.1050_bib46","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0002-9378(91)90645-8","article-title":"A selective serotonin reuptake inhibitor, fluoxetine hydrochloride, modulates the pulsatile release of prolactin in postmenopausal women","volume":"164","author":"Urban","year":"1991","journal-title":"Am J Obstet Gynecol"},{"key":"10.4065\/80.8.1050_bib47","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1177\/026988119701100410","article-title":"Changes in plasma prolactin during SSRI treatment: evidence for a delayed increase in 5-HT neurotransmission","volume":"11","author":"Cowen","year":"1997","journal-title":"J Psychopharmacol"},{"key":"10.4065\/80.8.1050_bib48","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0165-0327(97)00086-4","article-title":"Breast enlargement during chronic antidepressant therapy","volume":"46","author":"Amsterdam","year":"1997","journal-title":"J Affect Disord"},{"key":"10.4065\/80.8.1050_bib49","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S0278-5846(02)00259-2","article-title":"The effects of paroxetine and tianeptine on peripheral biochemical markers in major depression","volume":"26","author":"M\u00fcck-Seler","year":"2002","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.4065\/80.8.1050_bib50","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/00002826-199710000-00006","article-title":"Lack of adverse interactions between concomitantly administered selegiline and citalopram","volume":"20","author":"Laine","year":"1997","journal-title":"Clin Neuropharmacol"},{"key":"10.4065\/80.8.1050_bib51","first-page":"332","article-title":"Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder","volume":"22","author":"Shlik","year":"1997","journal-title":"J Psychiatry Neurosci"},{"key":"10.4065\/80.8.1050_bib52","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s002130050610","article-title":"Sertraline treatment does not increase plasma prolactin levels in healthy subjects [letter]","volume":"137","author":"Gordon","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"key":"10.4065\/80.8.1050_bib53","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000054954","article-title":"Effects of sertraline treatment on plasma cortisol, prolactin and thyroid hormones in female depressed patients","volume":"45","author":"\u0160agud","year":"2002","journal-title":"Neuropsychobiology"},{"key":"10.4065\/80.8.1050_bib54","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/00004714-199708000-00009","article-title":"The effect of fluvoxamine on serum prolactin and serum sodium concentrations: relation to platelet 5-HT2A receptor status","volume":"17","author":"Spigset","year":"1997","journal-title":"J Clin Psychopharmacol"},{"key":"10.4065\/80.8.1050_bib55","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/00004583-199207000-00032","article-title":"More fluoxetine experience [letter]","volume":"31","author":"Iancu","year":"1992","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.4065\/80.8.1050_bib56","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0025-6196(11)63132-7","article-title":"Reversible galactorrhea and prolactin elevation related to fluoxetine use","volume":"76","author":"Peterson","year":"2001","journal-title":"Mayo Clin Proc"},{"key":"10.4065\/80.8.1050_bib57","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/00004714-199408000-00007","article-title":"Attenuation of the prolactin-stimulating and hyperthermic effects of nefazodone after subacute treatment","volume":"14","author":"Walsh","year":"1994","journal-title":"J Clin Psychopharmacol"},{"issue":"5, pt 2","key":"10.4065\/80.8.1050_bib58","first-page":"209","article-title":"Failure of bupropion to affect prolactin or growth hormone in man","volume":"44","author":"Whiteman","year":"1983","journal-title":"J Clin Psychiatry"},{"key":"10.4065\/80.8.1050_bib59","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0165-1781(88)90059-5","article-title":"Effects of trazodone treatment on serotonergic function in depressed patients","volume":"24","author":"Price","year":"1988","journal-title":"Psychiatry Res"},{"key":"10.4065\/80.8.1050_bib60","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0278-5846(00)00165-2","article-title":"Effects of short and long-term lithium treatment on serum prolactin levels in patients with bipolar affective disorder","volume":"25","author":"Bast\u00fcrk","year":"2001","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.4065\/80.8.1050_bib61","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1210\/jcem-41-4-797","article-title":"Effects of morphine on serum growth hormone, cortisol, prolactin and thyroid stimulating hormone in man","volume":"41","author":"Tolis","year":"1975","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4065\/80.8.1050_bib62","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/0306-4530(84)90050-7","article-title":"Morphine inhibits cortisol and stimulates prolactin secretion in man","volume":"9","author":"Zis","year":"1984","journal-title":"Psychoneuroendocrinology"},{"key":"10.4065\/80.8.1050_bib63","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1365-2265.1979.tb02115.x","article-title":"Effects of heroin addiction on thyrotrophin, thyroid hormones and prolactin secretion in men","volume":"10","author":"Chan","year":"1979","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.4065\/80.8.1050_bib64","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0306-4530(79)90028-3","article-title":"Endocrine studies in heroin addicts","volume":"4","author":"Afrasiabi","year":"1979","journal-title":"Psychoneuroendocrinology"},{"key":"10.4065\/80.8.1050_bib65","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1124\/jpet.103.050682","article-title":"Suppressed prolactin response to dynorphin A1-13 in methadone-maintained versus control subjects","volume":"306","author":"Bart","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.4065\/80.8.1050_bib66","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1210\/endo-117-3-1096","article-title":"Mainly \u03bc-opiate receptors are involved in luteinizing hormone and prolactin secretion","volume":"117","author":"Panerai","year":"1985","journal-title":"Endocrinology"},{"key":"10.4065\/80.8.1050_bib67","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1210\/jcem-62-1-181","article-title":"Anterior pituitary hormone responses to a kappa-opioid agonist in man","volume":"62","author":"Pfeiffer","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4065\/80.8.1050_bib68","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000124712","article-title":"Effects of specific activation of mu-, delta- and kappa-opioid receptors on the secretion of luteinizing hormone and prolactin in the ovariectomized rat","volume":"45","author":"Leadem","year":"1987","journal-title":"Neuroendocrinology"},{"key":"10.4065\/80.8.1050_bib69","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/0024-3205(79)90534-4","article-title":"Interaction between opiates and hypothalamic dopamine on prolactin release","volume":"24","author":"Van Vugt","year":"1979","journal-title":"Life Sci"},{"key":"10.4065\/80.8.1050_bib70","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1210\/endo-106-1-76","article-title":"\u03b2-Endorphin-induced decrease in hypothalamic dopamine turnover","volume":"106","author":"van Loon","year":"1980","journal-title":"Endocrinology"},{"key":"10.4065\/80.8.1050_bib71","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/0024-3205(79)90411-9","article-title":"Morphine- and opioid peptide-induced inhibition of the release of dopamine from tuberoinfundibular neurons","volume":"25","author":"Gudelsky","year":"1979","journal-title":"Life Sci"},{"key":"10.4065\/80.8.1050_bib72","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0165-1781(90)90069-H","article-title":"Neuroendocrine measures of dopaminergic function in chronic cocaine users","volume":"33","author":"Lee","year":"1990","journal-title":"Psychiatry Res"},{"key":"10.4065\/80.8.1050_bib73","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1210\/jcem-69-6-1256","article-title":"Cocaine effects on pulsatile secretion of anterior pituitary, gonadal, and adrenal hormones","volume":"69","author":"Mendelson","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4065\/80.8.1050_bib74","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1055\/s-2007-1013583","article-title":"Effects of five days verapamil administration on serum GH and PRL levels","volume":"17","author":"Maestri","year":"1985","journal-title":"Horm Metab Res"},{"key":"10.4065\/80.8.1050_bib75","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/00000441-199211000-00004","article-title":"Effects of calcium channel blockade with verapamil on the prolactin responses to TRH, L-dopa, and bromocriptine","volume":"304","author":"Kamal","year":"1992","journal-title":"Am J Med Sci"},{"issue":"1, pt 1","key":"10.4065\/80.8.1050_bib76","first-page":"E96","article-title":"Mechanism of verapamil calcium channel blockade-induced hyperprolactinemia","volume":"270","author":"Kelley","year":"1996","journal-title":"Am J Physiol"},{"key":"10.4065\/80.8.1050_bib77","doi-asserted-by":"crossref","first-page":"66","DOI":"10.7326\/0003-4819-95-1-66","article-title":"Verapamil-induced hyperprolactinemia and galactorrhea","volume":"95","author":"Gluskin","year":"1981","journal-title":"Ann Intern Med"},{"key":"10.4065\/80.8.1050_bib78","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/0002-9149(83)90336-3","article-title":"Hyperprolactinemia-galactorrhea induced by verapamil [letter]","volume":"51","author":"Fearrington","year":"1983","journal-title":"Am J Cardiol"},{"key":"10.4065\/80.8.1050_bib79","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1046\/j.1365-2265.1996.00859.x","article-title":"Hyperprolactinaemia and verapamil: prevalence and potential association with hypogonadism in men","volume":"45","author":"Romeo","year":"1996","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.4065\/80.8.1050_bib80","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1136\/bmj.1.6019.1186","article-title":"Effect of methyldopa on prolactin and growth hormone","volume":"1","author":"Steiner","year":"1976","journal-title":"BMJ"},{"key":"10.4065\/80.8.1050_bib81","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1001\/jama.1976.03260470034022","article-title":"Increased prolactin levels during reserpine treatment of hypertensive patients","volume":"235","author":"Lee","year":"1976","journal-title":"JAMA"},{"key":"10.4065\/80.8.1050_bib82","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1210\/jcem-71-1-256","article-title":"Effect of angiotensin-converting enzyme inhibition on pituitary hormone responses to insulin-induced hypoglycemia in humans","volume":"71","author":"Winer","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4065\/80.8.1050_bib83","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1210\/jcem-47-3-675","article-title":"Clinical and endocrinological analyses of patients with galactorrhea and menstrual disorders due to sulpiride or metoclopramide","volume":"47","author":"Aono","year":"1978","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4065\/80.8.1050_bib84","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000179051","article-title":"Effect of chronic metoclopramide therapy on serum pituitary hormone concentrations","volume":"11","author":"Tamagna","year":"1979","journal-title":"Horm Res"},{"key":"10.4065\/80.8.1050_bib85","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1507\/endocrj1954.27.521","article-title":"Effects of domperidone on serum prolactin levels in human beings","volume":"27","author":"Fujino","year":"1980","journal-title":"Endocrinol Jpn"},{"key":"10.4065\/80.8.1050_bib86","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S0140-6736(77)91358-7","article-title":"Gynaecomastia with cimetidine [letter]","volume":"1","author":"Delle Fave","year":"1977","journal-title":"Lancet"},{"key":"10.4065\/80.8.1050_bib87","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0140-6736(77)90260-4","article-title":"Plasma-prolactin and cimetidine [letter]","volume":"2","author":"Petrillo","year":"1977","journal-title":"Lancet"},{"key":"10.4065\/80.8.1050_bib88","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(78)90229-5","article-title":"Serum-prolactin in patients receiving chronic oral cimetidine [letter]","volume":"1","author":"Spiegel","year":"1978","journal-title":"Lancet"},{"key":"10.4065\/80.8.1050_bib89","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/bmj.1.6110.409","article-title":"Cimetidine and serum prolactin","volume":"1","author":"Majumdar","year":"1978","journal-title":"BMJ"},{"key":"10.4065\/80.8.1050_bib90","first-page":"129","article-title":"Cimetidine and endocrine secretions: a short review","volume":"5","author":"Scarpignato","year":"1979","journal-title":"Drugs Exp Clin Res"},{"key":"10.4065\/80.8.1050_bib91","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(83)90022-3","article-title":"More about ranitidine and hyperprolactinaemia [letter]","volume":"2","author":"Lombardo","year":"1983","journal-title":"Lancet"},{"key":"10.4065\/80.8.1050_bib92","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/0140-6736(93)92729-D","article-title":"Hyperprolactinaemia during famotidine therapy [letter]","volume":"342","author":"Delpre","year":"1993","journal-title":"Lancet"},{"key":"10.4065\/80.8.1050_bib93","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S0140-6736(00)02697-0","article-title":"Galactorrhea and hyperprolactinemia associated with protease inhibitors [letter]","volume":"356","author":"Hutchinson","year":"2000","journal-title":"Lancet"},{"key":"10.4065\/80.8.1050_bib94","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(05)71275-7","article-title":"Galactorrhoea, hyperprolactinaemia, and protease inhibitors [letter]","volume":"357","author":"Montero","year":"2001","journal-title":"Lancet"},{"issue":"12, suppl","key":"10.4065\/80.8.1050_bib95","first-page":"1121","article-title":"Management of prolactinomas during pregnancy","volume":"44","author":"Molitch","year":"1999","journal-title":"J Reprod Med"},{"key":"10.4065\/80.8.1050_bib96","first-page":"8","article-title":"Incidence of hyperprolactinemia during oral contraceptive therapy","volume":"55","author":"Reyniak","year":"1980","journal-title":"Obstet Gynecol"},{"key":"10.4065\/80.8.1050_bib97","first-page":"506","article-title":"Hyperprolactinemia and contraception: a prospective study","volume":"65","author":"Luciano","year":"1985","journal-title":"Obstet Gynecol"},{"key":"10.4065\/80.8.1050_bib98","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0010-7824(76)90076-7","article-title":"Effects of oral contraceptive steroids on pituitary prolactin secretion","volume":"13","author":"Abu-Fadil","year":"1976","journal-title":"Contraception"},{"key":"10.4065\/80.8.1050_bib99","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2265.1984.tb03438.x","article-title":"Oral contraceptive agents do not affect serum prolactin in normal women","volume":"20","author":"Davis","year":"1984","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.4065\/80.8.1050_bib100","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1365-2265.1986.tb00754.x","article-title":"Effect of oral contraceptives on serum prolactin: a longitudinal study in 126 normal premenopausal women","volume":"24","author":"Hwang","year":"1986","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.4065\/80.8.1050_bib101","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0015-0282(16)59165-1","article-title":"Heterogeneous distribution of serum prolactin values in apparently healthy young women, and the effects of oral contraceptive medication","volume":"47","author":"Josimovich","year":"1987","journal-title":"Fertil Steril"},{"key":"10.4065\/80.8.1050_bib102","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0010-7824(91)90115-V","article-title":"Low estrogen oral contraceptives and the hypothalamo-pituitary axis","volume":"44","author":"De Leo","year":"1991","journal-title":"Contraception"},{"key":"10.4065\/80.8.1050_bib103","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0378-5122(82)90015-9","article-title":"Endocrinological features and endometrial morphology in climacteric women receiving hormone replacement therapy","volume":"4","author":"Grasso","year":"1982","journal-title":"Maturitas"},{"key":"10.4065\/80.8.1050_bib104","first-page":"202","article-title":"Hormonal and metabolic effects of transdermal estradiol\/progestagen administration in postmenopausal women","volume":"39","author":"Perrone","year":"1994","journal-title":"Int J Fertil Menopausal Stud"},{"key":"10.4065\/80.8.1050_bib105","first-page":"556","article-title":"Circulating hormone levels in menopausal women receiving different hormone replacement therapy regimens: a comparison","volume":"40","author":"Castel-Branco","year":"1995","journal-title":"J Reprod Med"},{"key":"10.4065\/80.8.1050_bib106","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000291502","article-title":"Prolactin serum levels in postmenopausal women receiving long-term hormone replacement therapy","volume":"44","author":"Foth","year":"1997","journal-title":"Gynecol Obstet Invest"},{"key":"10.4065\/80.8.1050_bib107","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1046\/j.1365-2265.1999.00857.x","article-title":"The effects of six months of treatment with a low-dose of conjugated oestrogens in menopausal women","volume":"51","author":"Schlegel","year":"1999","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.4065\/80.8.1050_bib108","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF03350657","article-title":"Effect of 1,25-dihydroxyvitamin D3 and nifedipine on prolactin release in normal man","volume":"8","author":"Verbeelen","year":"1985","journal-title":"J Endocrinol Invest"},{"key":"10.4065\/80.8.1050_bib109","series-title":"Prolactin: Basic and Clinical Correlates","first-page":"709","article-title":"Hypothalamic hyperprolactinemia: neuroendocrine regulation of prolactin secretion in patients with lesions of the hypothalamus and pituitary stalk","author":"Molitch","year":"1985"},{"key":"10.4065\/80.8.1050_bib110","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0002-9343(87)90373-1","article-title":"Misinterpretation of prolactin levels leading to management errors in patients with sellar enlargement","volume":"82","author":"Bevan","year":"1987","journal-title":"Am J Med"},{"key":"10.4065\/80.8.1050_bib111","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1210\/jc.80.12.3507","article-title":"Dynamics of prolactin secretion in patients with hypopituitarism and pituitary macroadenomas","volume":"80","author":"Arafah","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4065\/80.8.1050_bib112","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0889-8529(05)70057-8","article-title":"Current approaches to imaging of the sellar region and pituitary","volume":"28","author":"Naidich","year":"1999","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.4065\/80.8.1050_bib113","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1176\/appi.neuropsych.15.3.375","article-title":"Effectiveness of switching to quetiapine for neuroleptic-induced amenorrhea","volume":"15","author":"Takahashi","year":"2003","journal-title":"J Neuropsychiatry Clin NeuroSci"},{"key":"10.4065\/80.8.1050_bib114","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1192\/bjp.126.3.285","article-title":"Brom-ergocryptine in the treatment of phenothiazine-induced galactorrhea","volume":"126","author":"Beumont","year":"1975","journal-title":"Br J Psychiatry"},{"key":"10.4065\/80.8.1050_bib115","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000118184","article-title":"Effect of bromocriptine mesylate on induced hyperprolactinemia in stabilized psychiatric outpatients undergoing neuroleptic treatment","volume":"13","author":"Cohen","year":"1985","journal-title":"Neuropsychobiology"},{"key":"10.4065\/80.8.1050_bib116","first-page":"737","article-title":"Neuroleptic-associated hyperprolactinemia: can it be treated with bromocriptine?","volume":"37","author":"Smith","year":"1992","journal-title":"J Reprod Med"},{"key":"10.4065\/80.8.1050_bib117","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/BF03345068","article-title":"Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders","volume":"23","author":"Tollin","year":"2000","journal-title":"J Endocrinol Invest"},{"key":"10.4065\/80.8.1050_bib118","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4088\/JCP.v65n0207","article-title":"Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study","volume":"65","author":"Cavallaro","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.4065\/80.8.1050_bib119","first-page":"252","article-title":"Bromocriptine associated with symptom exacerbation during neuroleptic treatment of schizoaffective schizophrenia","volume":"43","author":"Frye","year":"1982","journal-title":"J Clin Psychiatry"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611615875?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611615875?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T07:24:45Z","timestamp":1709969085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611615875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":119,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["S0025619611615875"],"URL":"https:\/\/doi.org\/10.4065\/80.8.1050","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2005,8]]}}}